Clinical Nutrition Market Size is projected to reach USD 60.35 billion by 2030, growing at a CAGR of 6.3%: Straits Research
21 juil. 2022 14h50 HE
|
Straits Research
New York, United States, July 21, 2022 (GLOBE NEWSWIRE) -- A clinical nutrition product improves a patient's health. Necessary supplements such as minerals, vitamins, and other nutrients aid in the...
$179.34 Million by 2028, OPEP (Oscillating Positive Expiratory Pressure) Devices Market, 5.2% CAGR Lead by Mouthpiece PEP Devices - Exclusive Research Report by The Insight Partners
10 mai 2022 04h13 HE
|
The Insight Partners
New York, May 10, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Oscillating Positive Expiratory Pressure (OPEP) Devices Market Forecast to 2028 – COVID-19 Impact...
Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole
16 sept. 2021 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...
AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)
11 mai 2021 08h30 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome
24 févr. 2021 10h00 HE
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
10 sept. 2020 18h00 HE
|
Lyra Therapeutics
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
03 sept. 2020 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
05 août 2020 16h05 HE
|
Lyra Therapeutics
- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
04 août 2020 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs
04 août 2020 08h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...